Journalartikel

Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition


AutorenlisteDony, E.; Lai, Y-J.; Dumitrascu, R.; Pullamsetti, S. S.; Savai, R.; Ghofrani, H. A.; Weissmann, N.; Schudt, C.; Fockerzi, D.; Seeger, W.; Grimminger, F.; Schermuly, R. T.

Jahr der Veröffentlichung2008

Seiten599-610

ZeitschriftEuropean Respiratory Journal

Bandnummer31

Heftnummer3

ISSN0903-1936

Open Access StatusBronze

DOI Linkhttps://doi.org/10.1183/09031936.00002007

VerlagEuropean Respiratory Society


Abstract

Phosphodiesterase (PDE) inhibitors are currently under investigation for the therapy of pulmonary hypertension.

The present study was designed to investigate chronic effects of oral pumafentrine, a mixed selective PDE-3/4 inhibitor, in monocrotaline (MCT)-induced pulmonary hypertension in rats.

Treatment with pumafentrine (10 mg(.)kg(-1) daily) from week 4 to 6 after a single injection of MCT (60 mg(.)kg(-1)) partially reversed pulmonary hypertension and right heart hypertrophy in rats. In addition, small pulmonary arterial muscularisation, media hypertrophy and decrease in lumen area were largely reversed. Inhibition of smooth muscle proliferation under pumafentrine was demonstrated in vivo as was a pro-apoptotic effect of pumafentrine on vascular cells. Moreover, pumafentrine dose-dependently increased cyclic adenosine monophosphate levels and inhibited proliferation of cultured pulmonary arterial smooth muscle cells.

In conclusion, oral pumafentrine partially reverses monocrotaline-induced pulmonary hypertension, lung vascular remodelling and right heart hypertrophy in rats.




Zitierstile

Harvard-ZitierstilDony, E., Lai, Y., Dumitrascu, R., Pullamsetti, S., Savai, R., Ghofrani, H., et al. (2008) Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition, European Respiratory Journal, 31(3), pp. 599-610. https://doi.org/10.1183/09031936.00002007

APA-ZitierstilDony, E., Lai, Y., Dumitrascu, R., Pullamsetti, S., Savai, R., Ghofrani, H., Weissmann, N., Schudt, C., Fockerzi, D., Seeger, W., Grimminger, F., & Schermuly, R. (2008). Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. European Respiratory Journal. 31(3), 599-610. https://doi.org/10.1183/09031936.00002007



Schlagwörter


CYCLIC-NUCLEOTIDE PHOSPHODIESTERASESINHALED PROSTACYCLINMONOCROTALINEPROSTACYCLIN ANALOGSremodellingSMOOTHSMOOTH-MUSCLE-CELLSTHYROID EPITHELIAL-CELLSVASODILATORY RESPONSE


Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-10-06 um 09:44